Chongqing Zhifei Biological Products Toekomstige groei

Future criteriumcontroles 4/6

Chongqing Zhifei Biological Products zal naar verwachting groeien in winst en omzet met respectievelijk 45.1% en 17.3% per jaar. De winst per aandeel zal naar verwachting groeien met 43.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 19.2% zijn.

Belangrijke informatie

45.1%

Groei van de winst

43.7%

Groei van de winst per aandeel

Biotechs winstgroei	43.4%
Inkomstengroei	17.3%
Toekomstig rendement op eigen vermogen	19.2%
Dekking van analisten	Good
Laatst bijgewerkt	01 Nov 2024

Recente toekomstige groei-updates

Recent updates

Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Sep 30

Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Analysts Are More Bearish Than They Used To Be

Sep 03

Calculating The Fair Value Of Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122)

Aug 23

We Think Chongqing Zhifei Biological Products (SZSE:300122) Can Stay On Top Of Its Debt

Jul 26

Why Investors Shouldn't Be Surprised By Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Low P/E

May 21

Earnings Miss: Chongqing Zhifei Biological Products Co., Ltd. Missed EPS By 35% And Analysts Are Revising Their Forecasts

Apr 26

Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?

Mar 26

Winst- en omzetgroeiprognoses

SZSE:300122 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	50,147	9,311	11,072	10,243	9
12/31/2025	53,335	9,807	6,738	8,690	13
12/31/2024	32,201	3,312	1,986	13,525	2
9/30/2024	36,432	3,690	2,331	3,346	N/A
6/30/2024	46,731	6,044	5,500	6,512	N/A
3/31/2024	53,141	7,496	4,665	5,763	N/A
12/31/2023	52,918	8,070	7,862	8,996	N/A
9/30/2023	49,712	8,462	2,476	3,586	N/A
6/30/2023	44,356	8,070	4,357	5,546	N/A
3/31/2023	40,596	7,648	2,951	4,266	N/A
1/1/2023	38,264	7,539	536	1,989	N/A
9/30/2022	36,647	7,412	-360	1,175	N/A
6/30/2022	35,835	8,447	-1,151	596	N/A
3/31/2022	35,567	11,193	3,452	5,305	N/A
12/31/2021	30,652	10,209	6,575	8,508	N/A
9/30/2021	25,969	9,226	7,515	9,350	N/A
6/30/2021	21,368	7,287	8,050	9,627	N/A
3/31/2021	16,482	3,723	2,691	3,868	N/A
12/31/2020	15,190	3,301	2,670	3,497	N/A
9/30/2020	13,971	3,082	2,554	3,272	N/A
6/30/2020	12,542	2,724	1,038	1,604	N/A
3/31/2020	10,928	2,381	691	1,318	N/A
12/31/2019	10,587	2,366	794	1,367	N/A
9/30/2019	9,400	2,128	598	1,145	N/A
6/30/2019	8,195	1,916	247	764	N/A
3/31/2019	6,684	1,694	-422	82	N/A
12/31/2018	5,228	1,451	106	586	N/A
9/30/2018	4,068	1,234	-326	98	N/A
6/30/2018	2,969	943	N/A	170	N/A
3/31/2018	2,019	632	N/A	298	N/A
12/31/2017	1,343	432	N/A	204	N/A
9/30/2017	942	311	N/A	207	N/A
6/30/2017	707	192	N/A	126	N/A
3/31/2017	464	34	N/A	87	N/A
12/31/2016	446	33	N/A	90	N/A
9/30/2016	431	44	N/A	253	N/A
6/30/2016	512	101	N/A	207	N/A
3/31/2016	660	209	N/A	265	N/A
12/31/2015	713	197	N/A	223	N/A
9/30/2015	779	172	N/A	143	N/A
6/30/2015	805	160	N/A	165	N/A
3/31/2015	835	153	N/A	167	N/A
12/31/2014	801	148	N/A	161	N/A
9/30/2014	777	136	N/A	153	N/A
6/30/2014	735	124	N/A	179	N/A
3/31/2014	758	132	N/A	157	N/A
12/31/2013	780	130	N/A	222	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 300122 ( 45.1% per jaar) ligt boven de spaarquote ( 2.8% ).

Winst versus markt: De winst van 300122 ( 45.1% per jaar) zal naar verwachting sneller groeien dan de CN markt ( 26.1% per jaar).

Hoge groeiwinsten: De winst van 300122 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van 300122 ( 17.3% per jaar) zal naar verwachting sneller groeien dan de markt CN ( 13.8% per jaar).

Hoge groei-inkomsten: De omzet van 300122 ( 17.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 300122 zal naar verwachting over 3 jaar laag zijn ( 19.2 %).

Chongqing Zhifei Biological Products Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates fall by 23%

Consensus revenue estimates fall by 27%

Price target decreased by 22% to CN¥38.55

Price target decreased by 9.7% to CN¥49.16

Price target decreased by 8.3% to CN¥53.66

Consensus EPS estimates fall by 20%

Recent updates

Consensus revenue estimates fall by 23%

Investor sentiment deteriorates as stock falls 24%

Insufficient new directors

Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Chongqing Zhifei Biological Products Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 34%

Chongqing Zhifei Biological Products Co., Ltd. Approves Election of Zhang Xinrong as Independent Director

Consensus revenue estimates fall by 27%

Price target decreased by 22% to CN¥38.55

Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Analysts Are More Bearish Than They Used To Be

Calculating The Fair Value Of Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122)

Now 22% overvalued

Chongqing Zhifei Biological Products Co., Ltd. Announces Final Dividend on A Shares, Payable on 08 August 2024

Price target decreased by 9.7% to CN¥49.16

We Think Chongqing Zhifei Biological Products (SZSE:300122) Can Stay On Top Of Its Debt

Price target decreased by 8.3% to CN¥53.66

Chongqing Zhifei Biological Products Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Why Investors Shouldn't Be Surprised By Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Low P/E

Consensus EPS estimates fall by 20%

Earnings Miss: Chongqing Zhifei Biological Products Co., Ltd. Missed EPS By 35% And Analysts Are Revising Their Forecasts

Price target decreased by 7.4% to CN¥65.91

Chongqing Zhifei Biological Products Co., Ltd., Annual General Meeting, Jun 18, 2024

Investor sentiment deteriorates as stock falls 15%

Chongqing Zhifei Biological Products Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?

Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) announces an Equity Buyback for CNY 500 million worth of its shares.

Investor sentiment improves as stock rises 16%

Chongqing Zhifei Biological Products Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

New minor risk - Share price stability

Investor sentiment improves as stock rises 20%

Chongqing Zhifei Biological Products Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Price target decreased by 8.2% to CN¥67.08

Price target decreased by 7.7% to CN¥72.05

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 32%

EVE Energy Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 16 June 2023

Consensus revenue estimates increase by 16%

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

Price target decreased to CN¥121

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chongqing Zhifei Biological Products Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on July 15, 2022

Investor sentiment improved over the past week

Chongqing Zhifei Biological Products Co., Ltd. Approves Cash Dividend for the Year 2021

Consensus forecasts updated

Price target decreased to CN¥148

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target decreased to CN¥193

Consensus EPS estimates increase by 10%

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Third quarter 2021 earnings released: EPS CN¥1.82 (vs CN¥0.61 in 3Q 2020)

Insufficient new directors

Insufficient new directors

Second quarter 2021 earnings released: EPS CN¥2.85 (vs CN¥0.62 in 2Q 2020)

Investor sentiment deteriorated over the past week

Price target increased to CN¥219

Consensus revenue estimates increase to CN¥26.1b

First quarter 2021 earnings released: EPS CN¥0.59 (vs CN¥0.32 in 1Q 2020)

Investor sentiment deteriorated over the past week

Chongqing Zhifei Biological Products Co., Ltd. to Report Fiscal Year 2020 Results on Apr 20, 2021

New 90-day high: CN¥167

Market bids up stock over the past week

Price target lowered to CN¥201